β-Thalassemia and Diabetes Mellitus: Current State and Future Directions.

Autor:	Taneera J; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Mahgoub E; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Qannita R; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Alalami A; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Shehadat OA; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Youssef M; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Dib A; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Hajji AA; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Hajji AA; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Al-Khaja F; Dubai Thalassemia Center, Dubai, United Arab Emirates., Dewedar H; Dubai Thalassemia Center, Dubai, United Arab Emirates., Hamad M; University of Sharjah College of Health Sciences, Sharjah, United Arab Emirates.
Jazyk:	angličtina
Zdroj:	Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme [Horm Metab Res] 2024 Apr; Vol. 56 (4), pp. 272-278. Date of Electronic Publication: 2023 Oct 23.
DOI:	10.1055/a-2185-5073
Abstrakt:	β-Thalassemia major is a congenital hemoglobin disorder that requires regular blood transfusion. The disease is often associated with iron overload and diabetes mellitus, among other complications. Pancreatic iron overload in β-thalassemia patients disrupts β-cell function and insulin secretion and induces insulin resistance. Several risk factors, including family history of diabetes, sedentary lifestyle, obesity, gender, and advanced age increase the risk of diabetes in β-thalassemia patients. Precautionary measures such as blood glucose monitoring, anti-diabetic medications, and healthy living in β-thalassemia patients notwithstanding, the prevalence of diabetes in β-thalassemia patients continues to rise. This review aims to address the relationship between β-thalassemia and diabetes in an attempt to understand how the pathology and management of β-thalassemia precipitate diabetes mellitus. The possible employment of surrogate biomarkers for early prediction and intervention is discussed. More work is still needed to better understand the molecular mechanism(s) underlying the link between β-thalassemia and diabetes and to identify novel prognostic and therapeutic targets. Competing Interests: The authors declare that they have no conflict of interest. (Thieme. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu